EZH2 couples pancreatic regeneration to neoplastic progression

被引:99
作者
Mallen-St Clair, Jon [1 ]
Soydaner-Azeloglu, Rengin [1 ]
Lee, Kyoung Eun [1 ]
Taylor, Laura [1 ]
Livanos, Alexandra
Pylayeva-Gupta, Yuliya [1 ]
Miller, George [2 ]
Margueron, Raphael [1 ]
Reinberg, Danny [1 ,3 ]
Bar-Sagi, Dafna [1 ]
机构
[1] NYU, Sch Med, Dept Biochem, New York, NY 10016 USA
[2] NYU, Sch Med, Dept Surg, New York, NY 10016 USA
[3] Howard Hughes Med Inst, New York, NY 10016 USA
关键词
EZH2; pancreas; regeneration; cancer; TUMOR-CELL PROLIFERATION; ACINAR-CELL; BETA-CELL; EXPRESSION; CANCER; INFLAMMATION; METHYLATION; ENHANCER; HEDGEHOG; GENE;
D O I
10.1101/gad.181800.111
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Although the polycomb group protein Enhancer of Zeste Homolog 2 (EZH2) is well recognized for its role as a key regulator of cell differentiation, its involvement in tissue regeneration is largely unknown. Here we show that EZH2 is up-regulated following cerulein-induced pancreatic injury and is required for tissue repair by promoting the regenerative proliferation of progenitor cells. Loss of EZH2 results in impaired pancreatic regeneration and accelerates KRas(G12D)-driven neoplasia. Our findings implicate EZH2 in constraining neoplastic progression through homeostatic mechanisms that control pancreatic regeneration and provide insights into the documented link between chronic pancreatic injury and an increased risk for pancreatic cancer.
引用
收藏
页码:439 / 444
页数:6
相关论文
共 50 条
  • [21] EZH2 coupled with HOTAIR to silence MicroRNA-34a by the induction of heterochromatin formation in human pancreatic ductal adenocarcinoma
    Li, Chi-Han
    Xiao, Zhangang
    Tong, Joanna Hung-Man
    To, Ka-Fai
    Fang, Xiangdong
    Cheng, Alfred S. L.
    Chen, Yangchao
    INTERNATIONAL JOURNAL OF CANCER, 2017, 140 (01) : 120 - 129
  • [22] EZH2 Regulates Pancreatic Cancer Subtype Identity and Tumor Progression via Transcriptional Repression of GATA6
    Patil, Shilpa
    Steuber, Benjamin
    Kopp, Waltraut
    Kari, Vijayalakshmi
    Urbach, Laura
    Wang, Xin
    Kueffer, Stefan
    Bohnenberger, Hanibal
    Spyropoulou, Dimitra
    Zhang, Zhe
    Versemann, Lennart
    Boesherz, Mark Sebastian
    Brunner, Marius
    Gaedcke, Jochen
    Stroebel, Philipp
    Zhang, Jin-San
    Neesse, Albrecht
    Ellenrieder, Volker
    Singh, Shiv K.
    Johnsen, Steven A.
    Hessmann, Elisabeth
    CANCER RESEARCH, 2020, 80 (21) : 4620 - 4632
  • [23] EZH2 Inhibition to Counteract Oral Cancer Progression through Wnt/β-Catenin Pathway Modulation
    Campolo, Michela
    Scuderi, Sarah Adriana
    Filippone, Alessia
    Bova, Valentina
    Lombardo, Sofia Paola
    Colarossi, Lorenzo
    Sava, Serena
    Capra, Anna Paola
    De Gaetano, Federica
    Portelli, Marco
    Militi, Angela
    Esposito, Emanuela
    Paterniti, Irene
    PHARMACEUTICALS, 2024, 17 (08)
  • [24] EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations
    McCabe, Michael T.
    Ott, Heidi M.
    Ganji, Gopinath
    Korenchuk, Susan
    Thompson, Christine
    Van Aller, Glenn S.
    Liu, Yan
    Graves, Alan P.
    Della Pietra, Anthony, III
    Diaz, Elsie
    LaFrance, Louis V.
    Mellinger, Mark
    Duquenne, Celine
    Tian, Xinrong
    Kruger, Ryan G.
    McHugh, Charles F.
    Brandt, Martin
    Miller, William H.
    Dhanak, Dashyant
    Verma, Sharad K.
    Tummino, Peter J.
    Creasy, Caretha L.
    NATURE, 2012, 492 (7427) : 108 - +
  • [25] EZH2: a novel target for cancer treatment
    Duan, Ran
    Du, Wenfang
    Guo, Weijian
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2020, 13 (01)
  • [26] MicroRNA-101 inhibits human hepatocellular carcinoma progression through EZH2 downregulation and increased cytostatic drug sensitivity
    Xu, Leibo
    Beckebaum, Susanne
    Iacob, Speranta
    Wu, Gang
    Kaiser, Gernot M.
    Radtke, Arnold
    Liu, Chao
    Kabar, Iyad
    Schmidt, Hartmut H.
    Zhang, Xiaoyong
    Lu, Mengji
    Cicinnati, Vito R.
    JOURNAL OF HEPATOLOGY, 2014, 60 (03) : 590 - 598
  • [27] SASH1 knockdown suppresses TRAF6 ubiquitination to regulate hemangioma progression by mediating EZH2 degradation
    Yu, Xueyuan
    Cong, Nuonuo
    Liu, Xiangyu
    Wang, Rui
    Li, Daxu
    EXPERIMENTAL CELL RESEARCH, 2022, 418 (01)
  • [28] EZH2 as a potential target in cancer therapy
    McCabe, Michael T.
    Creasy, Caretha L.
    EPIGENOMICS, 2014, 6 (03) : 341 - 351
  • [29] EZH2: a pleiotropic protein
    Burmeister, Thomas
    BLOOD, 2016, 128 (07) : 888 - 889
  • [30] Mutations in EZH2 are associated with poor prognosis for patients with myeloid neoplasms
    Zhang, Qi
    Han, Qi
    Zi, Jie
    Ma, Jinlong
    Song, Huihui
    Tian, Yulu
    McGrath, Mary
    Song, Chunhua
    Ge, Zheng
    GENES & DISEASES, 2019, 6 (03) : 276 - 281